Thrombophilia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Thrombophilia}} | {{Thrombophilia}} | ||
{{CMG}}; {{AE}} {{asiri}} | {{CMG}}; {{AE}} {{asiri}} {{JK}} | ||
==Overview== | ==Overview== | ||
| Line 30: | Line 30: | ||
|} | |} | ||
{| class="wikitable" | |||
* | |'''Table 2: Enlist the recommendations for indefinite anticoagulation at a target INR 2–3''' <ref name="pmid11529700">{{cite journal| author=Bauer KA| title=The thrombophilias: well-defined risk factors with uncertain therapeutic implications. | journal=Ann Intern Med | year= 2001 | volume= 135 | issue= 5 | pages= 367-73 | pmid=11529700 | doi=10.7326/0003-4819-135-5-200109040-00013 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11529700 }} </ref> | ||
* | |- | ||
* | ! '''High-risk conditions''' | ||
* | |- | ||
* | | | ||
*Two or more spontaneous thromboses | |||
*One spontaneous thrombosis in the case of antithrombin deficiency or the antiphospholipid antibody syndrome | |||
*One spontaneous life-threatening thrombosis: Near-fatal PE; Cerebral, Mesenteric or Portal vein thrombosis | |||
*One spontaneous thrombosis at an unusual site: Mesenteric or Cerebral vein | |||
*One spontaneous thrombosis in the presence of more than a single genetic defect predisposing to a thromboembolic event | |||
|} | |||
==References== | ==References== | ||
Latest revision as of 07:22, 28 March 2021
|
Thrombophilia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Thrombophilia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Thrombophilia secondary prevention |
|
Risk calculators and risk factors for Thrombophilia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Asiri Ediriwickrema, M.D., M.H.S. [2] Jaspinder Kaur, MBBS[3]
Overview
Secondary prevention strategies following acute thrombosis in patients with thrombophilia include anticoagulation.
Secondary Prevention
- Long-term therapy to prevent recurrence:
- 90% risk reduction: The standard therapy for patients with DVT or PE typically includes anticoagulation with warfarin for 3– 12 months at a target INR between 2-3 after initial heparinization course.
- Recurrences are less common after 6–12 months of discontinuation of anticoagulant therapy and when the initial event is associated with a transient risk factor such as surgery, trauma, etc.
| Table 1: Enlist the indications for the secondary prevention[1][2][3][4][5][6][7] |
| Indications for secondary thromboprophylaxis |
|---|
|
| Table 2: Enlist the recommendations for indefinite anticoagulation at a target INR 2–3 [8] |
| High-risk conditions |
|---|
|
References
- ↑ Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R; et al. (2016). "Guidance for the treatment of deep vein thrombosis and pulmonary embolism". J Thromb Thrombolysis. 41 (1): 32–67. doi:10.1007/s11239-015-1317-0. PMC 4715858. PMID 26780738.
- ↑ DeLoughery TG. Hemostasis and Thrombosis: Springer International Publishing; 2014.
- ↑ Cohoon KP, Heit JA (2014). "Inherited and secondary thrombophilia". Circulation. 129 (2): 254–7. doi:10.1161/CIRCULATIONAHA.113.001943. PMC 3979345. PMID 24421360.
- ↑ Seligsohn U, Lubetsky A (2001). "Genetic susceptibility to venous thrombosis". N Engl J Med. 344 (16): 1222–31. doi:10.1056/NEJM200104193441607. PMID 11309638.
- ↑ Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S; et al. (2012). "Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e278S–325S. doi:10.1378/chest.11-2404. PMC 3278063. PMID 22315265.
- ↑ Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A; et al. (2002). "Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer". N Engl J Med. 346 (13): 975–80. doi:10.1056/NEJMoa012385. PMID 11919306.
- ↑ Agnelli G (2004). "Prevention of venous thromboembolism in surgical patients". Circulation. 110 (24 Suppl 1): IV4–12. doi:10.1161/01.CIR.0000150639.98514.6c. PMID 15598646.
- ↑ Bauer KA (2001). "The thrombophilias: well-defined risk factors with uncertain therapeutic implications". Ann Intern Med. 135 (5): 367–73. doi:10.7326/0003-4819-135-5-200109040-00013. PMID 11529700.